The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Bispecific antibody combinations reshape treatment strategies in multiple myeloma
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, discusses the rapidly expanding role of bispecific antibody combinations in multiple myeloma, highlighting the promising efficacy of BCMA-targeted therapies such as teclistamab alone or in combination with daratumumab. He reviews emerging Phase III data demonstrating significant progression-free and overall survival benefits and explains how patient-specific factors, including infection history, lung disease, and access to IVIG support, may influence the choice between BCMA-targeted and talquetamab-based strategies.
This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
Transcript
So I think that the BCMA bispecific antibodies are very promising, and there are several that are already available around the world. We’ve got teclistamab, we have talquetamab, we have elranatamab and we have linvoseltumab as well. And we now have two large phase three studies supporting the use of teclistamab with or without daratumumab in a similar patient population as the one that we just evaluated in the MonumenTAL-3 study...
So I think that the BCMA bispecific antibodies are very promising, and there are several that are already available around the world. We’ve got teclistamab, we have talquetamab, we have elranatamab and we have linvoseltumab as well. And we now have two large phase three studies supporting the use of teclistamab with or without daratumumab in a similar patient population as the one that we just evaluated in the MonumenTAL-3 study. So interestingly, giving teclistamab in patients relapsing for their first time or beyond was superior to standard of care therapy. And the combination of teclistamab with daratumumab was also clearly superior to typical standard of care therapy with both progression-free and overall survival advantages seen in both of these studies. So we’ve got teclistamab by itself with daratumumab, and now we’ve got talquetamab-based combinations coming onto the scene. They have distinct side effect profiles. So the BCMA bispecific antibodies have a high rate of higher-grade infection. So if you have a patient whose disease course has been characterized by multiple high-grade infections, you might want to gravitate towards a talquetamab-based strategy. If you have a patient with severe lung disease, they may not tolerate a respiratory tract infection well, in which case a talquetamab-based strategy would probably be preferred. You need to have access to IVIg therapy if you’re going to use a BCMA targeted by a specific antibody. So if you live in a part of the world that does not have access to that resource, a talquetamab-based approach may be better for that particular patient. But the data with teclistamab by itself and with daratumumab look amazing. So if a patient’s a good candidate for both, just given the unique side effects that we see with the talquetamab, a BCMA targeted strategy may be preferred.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
